Endocrine Abstracts

Introduction: Cushing’s disease (CD) is the most common cause of hypercortisolism. Therefore, the majority of studies focused on the efficacy and safety of novel steroidogenesis inhibitors included CD patients only. This is exactly the case with osilodrostat – new potent inhibitor of 11β-hydroxylase. However, approximately 10% of hypercortisolism result from cortisol-secreting adrenal adenoma. Data on potential differences in the treatment with osilodrostat betw...